Free shipping on all orders over $ 500

PF-04217903

Cat. No. M1766

All AbMole products are for research use only, cannot be used for human consumption.

PF-04217903 Structure
Synonym:

PF-4217903

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 69  USD69 In stock
1mg USD 30  USD30 In stock
5mg USD 60  USD60 In stock
10mg USD 95  USD95 In stock
50mg USD 280  USD280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to 142 nM. PF-04217903 (PF-4217903) demonstrated >1000 fold selectivity for c-Met compared with >150 kinases, making it one of the most selective c-Met inhibitors described to date. PF-04217903 (PF-4217903) inhibited tumor cell proliferation, survival, migration/invasion in MET amplified cell lines in vitro, and demonstrated marked antitumor activity in tumor models harboring either MET gene amplification or a HGF/c-Met autocrine loop at well-tolerated dose levels in vivo.

Product Citations
Customer Product Validations & Biological Datas
Source Nature (2015). Figure 3. PF-04217903 and INCB28060 (AbMole Bioscience)
Method mice treatment in vivo and histological evaluation
Cell Lines B16F10 cells
Concentrations 40mg/kg PF-04217903 and 50mg/kg INCB28060
Incubation Time 2 weeks
Results Systemic treatment of WT mice carrying B16F10 melanomas (which are dependent on MET14) with three different MET tyrosine-kinase inhibitors (PF-04217903, INCB28060 and JNJ-38877605), strongly reduced TAN recruitment .
Source Nature (2015). Figure 2. PF-04217903 and INCB28060 (AbMole Bioscience)
Method mice treatment in vivo and histological evaluation
Cell Lines B16F10 cells
Concentrations 40mg/kg PF-04217903
Incubation Time 2 weeks
Results "Systemic administration of PF-04217903 decreased the weight and volume of B16F10 melanomas by 36% and 54%, respectively. Instead, MET knockdown in cancer cells only, led to 58% and 75% inhibition of tumour growth and volume.TAN inhibition by PF-04217903 was comparable in both Met-silenced and scrambled B16F10 melanomas."
Protocol (for reference only)
Cell Experiment
Cell lines B16F1, Tib6, EL4, and LLC, and endothelial cells, HUVECs and C166
Preparation method Cell lines, including B16F1, Tib6, EL4, and LLC, and endothelial cells, HUVECs and C166, were seeded at 104 cells in each well of 24-well tissue culture–treated plates. Cells were grown in the standard media as described earlier. Cells were treated with different concentrations (2, 0.2, and 0.02 μmol/L) of sunitinib, PF-04217903, and combination of both compounds for 4 days. Efficacy of the compounds was measured by counting cells in a Coulter counter machine (BD Biosciences). Similar approach was applied to evaluate the role of HGF or VEGF on cell proliferation, using 3 different concentrations (10, 100, and 200 ng/mL) of each ligand.
Concentrations 2, 0.2, and 0.02 μmol/L
Incubation time 4 days
Animal Experiment
Animal models B16F10 tumour-bearing mice
Formulation 0.5% methylcellulose in saline
Dosages 40mg/kg PF-04217903
Administration oral
Chemical Information
Molecular Weight 372.38
Formula C19H16N8O
CAS Number 956905-27-4
Solubility (25°C) DMSO 15 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Cui JJ, et al. J Med Chem. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.

[2] Lee NV, et al. PLoS One. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation.

Related c-Met Products
Zurletrectinib

Zurletrectinib (ICP-723) is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of TRK-mediated related diseases.

ABN401 

ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM.

(Z)-Semaxanib

(Z)-Semaxanib is a potent tyrosine kinase inhibitor.

MET kinase-IN-2 

MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM.

BMS-817378

BMS-817378 is a potent and selective inhibitor of MET with IC50 of 1.7 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: PF-04217903, PF-4217903 supplier, c-Met, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.